Ultragenyx Pharmaceutical (0LIF) Ratios
Ultragenyx Pharmaceutical Ratios
GB:0LIF's free cash flow for Q2 2026 was $-98.00M. For the 2026 fiscal year, GB:0LIF's free cash flow was decreased by $-1.00M and operating cash flow was $-97.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.48 | 2.37 | 2.61 | 3.38 | 4.72 |
| Quick Ratio | 2.34 | 2.24 | 2.49 | 3.28 | 4.63 |
| Cash Ratio | 1.13 | 0.50 | 0.76 | 0.51 | 1.70 |
| Solvency Ratio | -0.34 | -0.43 | -0.48 | -0.58 | -0.73 |
| Operating Cash Flow Ratio | -1.21 | -1.20 | -1.69 | -1.46 | -1.87 |
| Short-Term Operating Cash Flow Coverage | -5.75 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -654.00M | $ -424.04M | $ -483.42M | $ -309.05M | $ 256.77M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.83 | 0.03 | 0.03 | 0.02 | 0.03 |
| Debt-to-Equity Ratio | -15.95 | 0.16 | 0.16 | 0.09 | 0.05 |
| Debt-to-Capital Ratio | 1.07 | 0.14 | 0.14 | 0.08 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 1.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -19.15 | 5.89 | 5.41 | 4.38 | 1.65 |
| Debt Service Coverage Ratio | -3.34 | -7.46 | -7.80 | -15.02 | -13.98 |
| Interest Coverage Ratio | -8.63 | -8.50 | -8.62 | -15.09 | -12.97 |
| Debt to Market Cap | 0.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 13.57 | 1.14 | 1.48 | 1.07 | 1.05 |
| Net Debt to EBITDA | -1.78 | 0.28 | 0.33 | 0.16 | 0.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.80% | 86.30% | 89.59% | 92.21% | 95.44% |
| EBIT Margin | -75.63% | -90.06% | -124.92% | -181.30% | -120.53% |
| EBITDA Margin | -70.43% | -83.72% | -118.93% | -176.28% | -116.77% |
| Operating Profit Margin | -79.49% | -95.67% | -131.08% | -178.60% | -108.63% |
| Pretax Profit Margin | -84.84% | -101.31% | -140.12% | -193.14% | -128.91% |
| Net Profit Margin | -85.44% | -101.60% | -139.70% | -194.71% | -129.20% |
| Continuous Operations Profit Margin | -85.44% | -101.60% | -139.70% | -194.71% | -129.20% |
| Net Income Per EBT | 100.70% | 100.28% | 99.70% | 100.81% | 100.23% |
| EBT Per EBIT | 106.73% | 105.90% | 106.90% | 108.14% | 118.66% |
| Return on Assets (ROA) | -37.53% | -37.86% | -40.69% | -45.77% | -29.82% |
| Return on Equity (ROE) | 718.75% | -222.95% | -220.26% | -200.69% | -49.21% |
| Return on Capital Employed (ROCE) | -46.60% | -46.23% | -47.02% | -50.53% | -28.47% |
| Return on Invested Capital (ROIC) | -43.53% | -45.83% | -46.40% | -50.07% | -28.23% |
| Return on Tangible Assets | -43.83% | -44.44% | -47.38% | -52.76% | -33.70% |
| Earnings Yield | -25.35% | -14.94% | -17.25% | -21.84% | -7.96% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.23 | 4.60 | 5.92 | 8.98 | 12.36 |
| Payables Turnover | 3.52 | 1.98 | 1.07 | 0.65 | 0.93 |
| Inventory Turnover | 2.10 | 1.70 | 1.33 | 1.06 | 0.99 |
| Fixed Asset Turnover | 2.52 | 2.11 | 1.49 | 1.40 | 1.99 |
| Asset Turnover | 0.44 | 0.37 | 0.29 | 0.24 | 0.23 |
| Working Capital Turnover Ratio | 1.29 | 1.21 | 0.81 | 0.56 | 0.39 |
| Cash Conversion Cycle | 156.55 | 109.09 | -4.07 | -172.13 | 8.85 |
| Days of Sales Outstanding | 86.23 | 79.36 | 61.69 | 40.63 | 29.53 |
| Days of Inventory Outstanding | 174.13 | 214.10 | 274.25 | 344.97 | 370.08 |
| Days of Payables Outstanding | 103.81 | 184.36 | 340.01 | 557.73 | 390.77 |
| Operating Cycle | 260.36 | 293.46 | 335.94 | 385.60 | 399.62 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.73 | -4.57 | -6.46 | -5.44 | -5.00 |
| Free Cash Flow Per Share | -4.79 | -4.66 | -7.09 | -7.53 | -6.07 |
| Dividend Paid and CapEx Coverage Ratio | -77.67 | -55.29 | -10.15 | -2.60 | -4.63 |
| Capital Expenditure Coverage Ratio | -77.67 | -55.29 | -10.15 | -2.60 | -4.63 |
| Operating Cash Flow Coverage Ratio | -0.37 | -10.27 | -11.00 | -12.04 | -8.07 |
| Operating Cash Flow to Sales Ratio | -0.69 | -0.74 | -1.09 | -1.05 | -0.96 |
| Free Cash Flow Yield | -20.81% | -11.07% | -14.83% | -16.26% | -7.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.95 | -6.69 | -5.80 | -4.58 | -12.56 |
| Price-to-Sales (P/S) Ratio | 3.37 | 6.80 | 8.10 | 8.92 | 16.22 |
| Price-to-Book (P/B) Ratio | -28.35 | 14.92 | 12.77 | 9.19 | 6.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.80 | -9.03 | -6.74 | -6.15 | -13.84 |
| Price-to-Operating Cash Flow Ratio | -4.87 | -9.20 | -7.41 | -8.51 | -16.83 |
| Price-to-Earnings Growth (PEG) Ratio | 0.54 | 0.28 | 0.31 | -0.09 | -0.11 |
| Enterprise Value Multiple | -6.56 | -7.84 | -6.48 | -4.90 | -13.25 |
| Enterprise Value | 3.11B | 3.68B | 3.35B | 3.14B | 5.44B |
| EV to EBITDA | -6.56 | -7.84 | -6.48 | -4.90 | -13.25 |
| EV to Sales | 4.62 | 6.56 | 7.71 | 8.64 | 15.47 |
| EV to Free Cash Flow | -6.59 | -8.72 | -6.42 | -5.96 | -13.20 |
| EV to Operating Cash Flow | -6.67 | -8.87 | -7.05 | -8.25 | -16.05 |
| Tangible Book Value Per Share | -2.97 | 0.44 | 0.88 | 2.12 | 11.02 |
| Shareholders’ Equity Per Share | -0.81 | 2.82 | 3.74 | 5.04 | 13.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | 0.00 | -0.01 | -0.00 |
| Revenue Per Share | 6.83 | 6.19 | 5.90 | 5.20 | 5.18 |
| Net Income Per Share | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.01 | 1.00 |
| Interest Burden | 1.12 | 1.12 | 1.12 | 1.07 | 1.07 |
| Research & Development to Revenue | 1.11 | 1.25 | 1.49 | 1.94 | 1.41 |
| SG&A to Revenue | 0.52 | 0.57 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.23 | 0.28 | 0.31 | 0.36 | 0.30 |
| Income Quality | 0.81 | 0.73 | 0.78 | 0.54 | 0.75 |
Currency in USD
